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Background/Aims: The aim of this study was to evaluate the 
seroconversion rate of a hepatitis A virus (HAV) vaccination 
in patients with hepatitis B virus (HBV)-related chronic liver 
disease (CLD). Methods: Analyses were conducted using 
clinical records from 94 patients with chronic HBV infection 
who were seronegative for IgG anti-HAV antibodies between 
September 2008 and June 2009. Two doses of an HAV vac-
cine were administered 24 weeks apart. A third vaccine dose 
was administered only for patients seronegative for anti-HAV 
antibodies at week 48. Results: The seroconversion rate of 
anti-HAV following the two-dose vaccination was 86.17%. The 
seroconversion rate of anti-HAV was not signiﬁ  cantly different 
according to age or status of liver disease. The rate was high-
er in female than in male patients. A third HAV vaccine dose 
was administered to 13 patients seronegative for anti-HAV 
after the two-dose regimen, and 84.62% of these patients 
showed seroconversion at week 72. Conclusions: HAV vac-
cination is effective in most Korean patients with HBV-related 
CLD, and it might be necessary to evaluate three-dose vac-
cination approach for non-responders to the conventional 
regimen to maximize the success of an HAV vaccination pro-
gram. (Gut Liver 2011;5:217-220)
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cirrhosis; Hepatitis A virus vaccination
INTRODUCTION
Hepatitis A virus (HAV) infection is an epidemiologically 
important disease and it causes acute hepatitis in humans with 
a worldwide distribution. The number of cases of adult hepati-
tis A has progressively been increasing during the last several 
decades in Korea since Korea has undergone a change from hy-
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perendemicity to intermediate endemicity for hepatitis A virus 
infection due to the improvements of the socioeconomic and 
sanitation conditions.
1-3
Lifelong protective antibodies are present after hepatitis A vi-
rus infection.
4 The clinical manifestations of hepatitis A depend 
on the age of the host: less than 30% of infected young children 
showed symptomatic hepatitis, while about 80% of infected 
adults manifested with severe acute hepatitis with remarkably 
elevated levels of serum aminotransferases.
5
Although the overall case-fatality rate of acute HAV among 
persons of all ages is only 0.01% to 0.3%,
6-8 it is higher (1.8%) 
among adults who are 50 years of age or older.
7 Several studies 
have also shown that super-infection with HAV in patients with 
chronic hepatitis B virus (HBV) infection results in significant 
increases in severe liver disease, acute liver failure and mortal-
ity.
9-11 Korea is still highly endemic for hepatitis B infection, and 
this infection exhibits a strong tendency to turn towards chronic 
liver disease (CLD) when it is acquired during infancy or early 
childhood, and therefore vaccination for HAV is recommended 
for the patients with CLD. However, there are only limited stud-
ies that have evaluated the efficacy of HAV vaccine in the pa-
tients with CLD.
The aim of this study was to evaluate the seroconversion rate 
of IgG HAV antibody (anti-HAV) after having received the cur-
rent HAV vaccination in the patients with HBV-related CLD in 
Korea. 
MATERIALS AND METHODS
1. Study design, population and collection of data 
We identified a total of 918 patients with CLD and who had 
undergone IgG anti-HAV testing between September 2008 and 
June 2009 at Samsung Medical Center, Seoul, Korea. Among 
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them, 86.7% (796/918) of the patients already had seropositive 
anti-HAV. Ninety-four patients with HBV-related CLD were 
selected from 122 patients who showed seronegativity for IgG 
anti-HAV. The eligibility criteria included HBV surface antigen 
(HBsAg) positivity for at least 6 months. The patients with hu-
man immunodeficiency virus or hepatitis C virus infection and 
a past medical history of acute viral hepatitis A infection or 
HAV vaccination were excluded from this study. 
The statuses of the underlying liver diseases were classified 
into chronic hepatitis and liver cirrhosis (LC). The diagnosis of 
LC was made if any one of the following findings was met: 
1) compatible intraoperative gross findings or histologically 
compatible findings, 2) evidence of portal hypertension in the 
patients with liver disease, 3) compatible radiologic findings and 
platelet counts less than 100×10
9/L.
Blood samples for IgG anti-HAV testing were collected at 
weeks 0, 24, 48, and 72 after the first injection of vaccine.
The Institutional Review Board of Samsung Medical Center 
approved this retrospective study and informed consent was 
waived. 
2. Materials
The vaccine used in this study was Havrix (GlaxoSmithKline, 
Philadelphia, PA, USA), which contains 1,440 enzyme-linked 
immunosorbent assay units of inactivated HM175 HAV per mil-
liliter. Vaccination was implemented according to the recom-
mended 2-dose schedule, and this consists of a primary dose 
of 1 mL followed by a booster dose of 1 mL 6 months later. At 
week 48 after the first injection, only the patients with serone-
gative IgG anti-HAV received a third dose of 1 mL of vaccine. 
The vaccine was administered in the deltoid muscle to all pa-
tients. 
3. Laboratory procedures 
Commercially available immunoassays (Anti-HAV IgG IRMA 
kit, North Institute of Biological Technology, Beijing, China; 
ARCHITECT HBsAg assay, Abbott Laboratories, Sligo, Ireland) 
were used to detect IgG anti-HAV and HBsAg. 
4. Statistical analysis
The categorical and continuous variables were compared us-
ing Fisher’s exact test and independent two-sample t-tests, re-
spectively, for comparing the clinical characteristics between the 
seropositive anti-HAV and seronegative anti-HAV groups after 
HAV vaccination. 
A p value of less than 0.05 was considered statistically sig-
nificant. All the statistical analyses were run on SPSS version 
15.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS 
1. Patient demographics 
The patient characteristics are detailed in Table 1. The mean 
age of the patients was 36.7 years (range, 20 to 58 years). A 
male preponderance (76.6%) was observed and the vast majority 
of patients had chronic viral hepatitis B (79.79%). The overall 
seroconversion rate of IgG anti-HAV in the patients with CLD 
after the recommended two doses of HAV vaccine was 86.17% 
(81/94). None of the patients showed any serious adverse events 
associated with the vaccine. 
2. Seroconversion rate of IgG anti-HAV according to age, 
gender, and status of liver disease after two doses of 
HAV vaccine
The seroconversion rate of IgG anti-HAV according to age, 
gender, and status of liver disease in the patients with HBV-
related CLD after two doses of HAV vaccine is shown in Table 2. 
There was no significant difference in age between the seroposi-
tive and seronegative anti-HAV groups (mean age, 37.1 vs 34.2 
years, respectively; p=0.294). The seroconversion rate was high-
er for the female patients than that for the male patients (100% 
Table 1. Patient Characteristics
Variable  No. of patients (%)
Mean age (range), yr  36.7±9.1 (20–58) 
Gender 
  Male    72 (76.60) 
  Female    22 (23.40) 
Chronic liver disease 
  Chronic hepatitis B    75 (79.79) 
  HBV-related liver cirrhosis    19 (20.21) 
CTP class A  94 (100)
Seroconversion rate of IgG anti-HAV 
 after two doses of HAV vaccination 
   81 (86.17)
HBV, hepatitis B virus; CTP, Child–Turcotte–Pugh; HAV, hepatitis A 
virus.
Table 2. Seroconversion Rate of IgG Anti-HAV with Respect to Age, 
Gender, and Status of Liver Disease in Patients with HBV-Related 
CLD Following Two HAV Vaccine Doses
Characteristic
Anti-HAV 
positive, 
No. (%)
Anti-HAV 
negative, 
No. (%)
p-value
Age, mean±SD, yr 37.1±7.2 34.2±9.3 0.294
Gender 0.034
  Male 59/72 (81.94) 13/72 (18.06)
  Female  22/22 (100)   0/22 (0)
Status of liver disease  0.722
  Chronic viral hepatitis B 65/75 (86.67) 10/75 (13.33)
  HBV-related liver cirrhosis 16/19 (84.21)   3/19 (15.79)
HAV, hepatitis A virus; HBV, hepatitis B virus; CLD, chronic liver dis-
ease.Cho HC, et al: Seroconversion Rate of HAV Vaccination  219
vs 81.94%, respectively; p=0.034). As for the status of the liver 
disease, the chronic viral hepatitis B and HBV related LC groups 
showed no significant difference of the seroconversion rate after 
vaccination (86.67% vs 84.21%, respectively; p=0.722).
3. Seroconversion rate of IgG anti-HAV after three doses of 
HAV vaccination 
At weeks 48 after the first injection, an additional third dose 
of HAV vaccination was administered to only the 13 patients 
who showed seronegativity for IgG anti-HAV even after two 
doses of vaccination. The mean age of these 13 patients was 
34±7.2 years (range, 21 to 45 years) and all of them were male. 
They consisted of ten patients with chronic hepatitis and three 
patients with LC. One patient with chronic hepatitis and one 
with LC did not attend the follow-up visit at week 72. These two 
patients were considered to have failed seroconversion at the 
specified time points. On an intention-to-treat basis, the sero-
conversion rate for these patients was 84.62% (11/13). 
DISCUSSION
Based on the potential risk for fulminant hepatic failure 
and death from acute HAV superinfection, the 1996 Advisory 
Committee on Immunization Practices recommended HAV 
vaccination for all patients with chronic liver disease.
12 These 
recommendations have also been endorsed by the World Health 
Organization,
13 the National Institute of Health
14 and others. 
There are few published studies that have evaluated the safety 
and efficacy of HAV vaccine in patients with chronic liver 
diseases.
15-20 For the patients with well-compensated disease, 
the vaccine shows the same safety and immunogenicity profile 
as that in the general population, and the seroconversion rate 
reaches over 80% or 90% after the complete vaccination course. 
Lee et al.
15 reported that the seroconversion rate was 100% in 
chronic liver disease patients after two doses of vaccine. In that 
study, 93.3% of the patients (56/60) had HBV infection, and the 
severity or chronicity of the HBV-related liver disease was not 
mentioned. In another study by Keeffe et al.
16, 94% of all those 
patients with liver disease and who were vaccinated had sero-
conversion after two doses of vaccine that were given 6 months 
apart. However, only a minority of patients in that study had 
chronic HBV infection (10%). Tsang and Sung
19 reported that 
the seroconversion rate was 80% in 65 patients with chronic 
HBV infection after two doses of vaccine. Although that study 
included patients with LC, the Child-Pugh classes of them were 
not provided. 
In patients with advanced cirrhosis and in transplant patients, 
the vaccination appeared less effective, and seroconversion 
is achieved in only about 50% of the cases.
17,18,20 Arguedas et 
al.
20 reported that for patients with compensated liver disease, 
including the patients with chronic hepatitis or the Child-Pugh 
class A patients, a 98% response rate was achieved after a two-
dose course of vaccination, as compared with a 65.7% response 
rate for patients with decompensated liver disease. Among this 
latter group, the Child-Pugh class B patients had a response rate 
of 71.4%, whereas a response of 57% was achieved in the Child-
Pugh class C patients. In that study, the majority of the patients 
had chronic viral liver disease, yet the specific viral etiologies 
were not provided. 
In our study, the seroconversion rate of IgG anti-HAV in 94 
Korean patients with HBV-related CLD after the recommended 
two-dose vaccination was 86.17%, which was quite comparable 
to that of other studies.
15,16,19,20
In this current study, the seroconversion rate of anti-HAV af-
ter two-dose vaccination was not significantly different accord-
ing to age and this result is consistent with the results of other 
studies. Reuman et al.
21 reported that adults older than 40 years 
appear to respond less well than do younger adults to a single 
dose of hepatitis A vaccine, but both groups of adults responded 
equally well after two doses of vaccine.
The seroconversion rate of anti-HAV after two-dose vaccina-
tion was not significantly different according to the status of 
liver disease. This is probably attributable to the fact that all the 
patients had Child-Pugh class A, compensated liver disease. 
As has also been reported in another clinical trial,
16 the female 
patients in this study exhibited a higher seroconversion rate 
than did the male patients. Although the exact reason could not 
be found, the female patients usually have lower body surface 
area and conventional dose of vaccination might be relatively 
higher for them. 
Inactivated hepatitis A vaccines have been commercially 
available in Korea since 1997. Studies have shown that they are 
safe and effective in healthy subjects and they also seem equally 
safe in patients with chronic liver diseases, as mentioned earlier. 
Initially, it was recommended that individuals should be vac-
cinated with three doses at weeks 0, 4, and 24 and thereafter a 
single double dose regimen at weeks 0 and 24 has been found 
to be just as immunogenic.
22 Nearly all the patients receiving a 
single double dose regimen achieved seroconversion, with pro-
tective levels of antibody persisting for up to 12 months
23 and a 
single double dose regimen has become the commonly recom-
mended regimen of vaccination. 
In the current study, 13.83% of the patients (13/94) were still 
seronegative for IgG anti-HAV even after the recommended two 
doses of vaccination. They received an additional third dose of 
vaccination and seroconversion rate was 84.62% (11/13) on 
an intension-to-treat basis. To the best of our knowledge, this 
three-dose regimen of vaccination at weeks 0, 24, and 48 has 
never been tried in other studies and the current study suggests 
the possible benefit of this regimen for the patients with CLD 
and who are non-responsive to the conventional two-dose regi-
men of HAV vaccination.
The current study has a couple of limitations. First, since less 
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24, the seroconversion rate and the factors affecting seroconver-
sion after the first dose of vaccination could not be evaluated. 
Second, only Child-Pugh class A cirrhotic patients were includ-
ed in this study, and they might not properly represent the fea-
tures of the patients with HBV-related liver cirrhosis. Third, the 
current study included a relatively small number of HBV-related 
CLD patients and the study was performed at a single medical 
center. So, the patients may not be representative of the whole 
CLD population of Korea. A large population based prospective 
controlled study to confirm our results should be considered. 
In conclusion, the recommended two-dose HAV vaccination 
is effective in most Korean patients with HBV-related CLD and it 
might be necessary to evaluate three-dose vaccination approach 
for patients who were non-responsive to the conventional regi-
men to maximize the success of a vaccination program for 
HAV. 
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